T. Rowe Price Associates
STLN

T. Rowe Price Associates’s Starling Oncology STLN Stock Holding History

T. Rowe Price Associates’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Buy
61,750
+13,479
+28% +$56.6K ﹤0.01% 2806
2026
Q1 		$149K Buy
48,271
+10,269
+27% +$31.5K ﹤0.01% 2915
2025
Q4 		$136K Buy
38,002
+8,238
+28% +$30.6K ﹤0.01% 2904
2025
Q3 		$104K Hold
29,764
– – ﹤0.01% 2914
2025
Q2 		$62K Buy
+29,764
New +$74.4K ﹤0.01% 2976

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

T. Rowe Price Associates's STLN Position: Q2 2026 in Review

T. Rowe Price Associates increased its Starling Oncology (STLN) stake by 28% in Q2 2026, buying an estimated $56.6K and bringing the position to 61,750 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #2806.

T. Rowe Price Associates first reported a position in STLN in Q2 2025 and has held it in 5 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • T. Rowe Price Associates held 61,750 shares of Starling Oncology worth $336K as of Q2 2026.
  • T. Rowe Price Associates bought 13,479 Starling Oncology shares in Q2 2026, an estimated $56.6K.
  • Starling Oncology made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2806 holding.
  • T. Rowe Price Associates first reported a position in Starling Oncology in Q2 2025 and has held it in 5 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.